IQEAP - IQoro® Early Adopters Programme

Showing that it works in the UK healthcare pathway

Many have been successfully treated
IQoro® is used by thousands of people to treat the symptoms of dysphagia – whether after stroke, head injury or for many other reasons. Additionally, patients use it to address reflux, GERD (GORD) and LPR, and snoring and Obstructive Sleep Apnoea. The evidence base is robust and clear – the treatment works!

But
Within the UK, healthcare professionals, the NHS, NICE and others highlight that most of these patients are either private individuals, or in healthcare systems in other countries. Therefore, we need to address the question, ”Will IQoro® work just as well in the UK healthcare pathway?” The physiology is similar across Sweden and the UK, but there may be differences in how it can be deployed in the two different healthcare systems.

IQEAP
At the end of 2017, it was apparent that there were a number of NHS and other UK institutions that wanted to get started on using the IQoro® treatment with patients that matched the condition symptoms that it treats best. At the same time NICE asked for evidence of successful use in the UK NHS dysphagia healthcare pathway. A dozen or so institutions decided to launch service evaluations where IQoro® treatment could be introduced in a controlled way through a number of SLTs to a limited cohort of patients. That’s the IQEAP programme.

How can we help?
The service evaluations belong to the hospitals and institutions conducting them, not to IQoro®. The leadership in the SLT groups decide the size and shape and details of their project. When statring the programme, it soon became obvious that a lot of the initial questions were common across several institutions, and that a lot of wheels were being reinvented. “How do I explain to my R&D department why this is a service evaluation of IQoro® and not a formal clinical study?”, “What exclusion and inclusion criteria do I want to apply?”, “How will I measure outcome measures and the SLT experience?”, “How do I map a healthcare pathway with and without IQoro® intervention?” And more.

Below, we provide a list of example documents that you can use if you want to, that may make the process simpler for you, and your life easier. We hope this helps!

1. What is an IQEAP? 
including why it is a service evaluation not a randomised control trial.

2. Inclusion and exclusion considerations 
for IQoro® treatment with dysphagia patients and others

3. Sample pathways
Sample community IQoro® dysphagia pathway
Sample in-patient IQoro® dysphagia pathway

4. IQoro® feasibility kit for healthcare professionals - agreement 
The company supplies demo products for healthcare professionals to use in patient feasibility assessments. This is part of accredited IQEAP Service Evaluations. This agreement regulates the responsibilities from both sides when the IQoro® products are supplied.

5. Infection control procedure for feasibility kits 
IQoro® devices used for patient feasibility testing will need to be kept clean and ready-for-use. Here is a procedure recommended by one NHS SLT department.

6. Tips on how to introduce IQoro® to a patient 
A guide for the professional that is about to commence deploying IQoro® to patients.

7. Patient consent form 
Optional – may be required by some departments.

8. How to train with your IQoro® 
A very simplified ‘one page’ guide for the self-administered patient with functional lips and arms.

9. How to train with your IQoro® using a jaw grip 
A simplified ‘one page’ guide for the self-administered patient with functional arms and hands, but weak lip strength.

10. I’m not sure I’m training properly 
A step-by-step guide to the training process to be used as a troubleshooting guide for those not sure that they are getting it right.

11. How to assist someone to train with IQoro® 
A guide for professionals and carers that will help a patient who has insufficient lip and arm strength.

12. A4-sized training diary sheet 
A journal sheet is included in the booklet that comes with each device, but for some patients this larger version may be preferred.

13. Pre-Procurement Questionnaire
May be required by NHS for procurement purposes.

14. Scientific research behind IQoro® training 
The entire library of scientific publications can be found on the website. This document reproduces the abstracts of a dozen or so of the relevant clinical studies, and may be useful for some audiences.

15. IQoro® - How it works and the primacy of its neurological effect 
Many SLTs using IQoro® for the first time will be curious as to how it can be so effective in cases where patients have had problems for years after stroke, or how the device can address so many condition groups. This document, developed with the support of Dr Mary Hägg, explains the key role of the neurological effects of IQoro® training.

16. IQEAP Patient experience 
Records the progress of patient treatment as experienced by the patient.

17. IQEAP SLT experience 
This document provides a record of how the SLT experienced the patient’s treatment with IQoro®. It is shown here in text format, but is also made available to therapists on-line in a Survey Monkey. Records the progress of patient treatment as experienced by the SLT.

18. Therapy outcome measures and tools 
NHS institutions use a variety of therapy outcome measures when assessing patients, including to test at baseline and end-of-treatment. The Royal College of Speech and Language Therapists have kindly provided this information to share.

 


IQoro® treats the causes of your Hiatal hernia - not just the symptoms

iqoro-behandling-hiatusbrack

 

 

 

 

 

 

 

 


 

Buy your IQoro

 

IQoro® is a neuromuscular training device. It allows you to strengthen the muscles that you can’t usually train - at least not by consciously controlling these muscles. The instructions to activate these ‘involuntary’ muscles come only from autonomic brain signals. That’s what IQoro® stimulates.

All it takes is 90 seconds exercise per day. IQoro® uses the body’s natural nerve pathways to activate the muscles from the face, oral cavity, pharynx, esophagus and down to the diaphragm where your hernia is situated.

Your injured muscle in the diaphragm is strengthened, and gradually your symptoms will disappear as you address their cause. Some maintenance training will be required after your symptoms have gone to keep your original symptoms at bay.

 

 

Patented and made in Sweden




Internationally patented and manufactured in Sweden.

CE-märkt medicinteknisk produkt klass 1

 

 

CE marked, Class 1 Medical Device

IQoro® is based on many years’ scientific research, and is certified for sale and use in the EU and EEA countries.

Inga biverkningar

 

 

No side-effects

IQoro® naturally strengthens the musculature from the face, oral cavity, upper airways, esophagus down to the diaphragm and stomach without any side-effects.

 

 

 

    

Products
    Produced by:  Wikinggruppen